The present invention provides emulsion compositions comprising an continuous oil phase, a discontinuous aqueous phase and a plurality of microparticles. The composition may comprise a pharmaceutical active ingredient located in the oil phase, the particulate phase or the aqueous phase. The emulsion compositions have improved stability and coherence and are useful in the treatment of tumours by embolotherapy.

The invention provides a novel class of microparticles suitable for inducing or causing embolism to blood microvessels.

The present invention relates to a method for preparing beads comprising imaging agent. The present invention further provides beads highly useful for medical imaging.

The present invention relates to hydrogels comprising 1,2-diol or 1,3-diol groups acetalized with a radiopaque species of one or more covalently bound radiopaque halogens which are imageable during embolization therapy. The invention further relates to methods of making radiopaque polymers and radiopaque hydrogel microspheres to provide an imageable drug delivery system.

The present disclosure describes an imaging composition including porous silicon microparticles, and more particularly, to a biological tissue imaging composition including a composite in which oxidized porous silicon microparticles and silver nanoparticles are combined. Since a biological tissue imaging agent of the present invention, which includes a composite of oxidized porous silicon microparticles and silver nanoparticles, continuously provides an image signal without spreading in the body as compared to conventional imaging agents, it is possible to increase surgical stability by accurately identifying target tissues in vivo in an affected area.

A method of performing a radioembolization treatment includes injecting 402 a plurality of radioembolization particles into a bloodstream of a patient to treat a target tissue. Each radioembolization particle of the plurality of radioembolization particles includes a radioactive core and a radiopaque layer. The method also includes obtaining 404 an image of the target tissue and the radioembolization particles to determine 406 a dose of radioactivity delivered to the target tissue by the plurality of radioembolization particles. wherein the image is one of a computerized tomography (CT) image and an x-ray image.

The invention relates to non-biodegradable embolisation microspheres comprising a cross-linked matrix, the matrix being based on at least: a) from 20% to 95% of hydrophilic monomer; b) from 1% to 15% of a non-biodegradable hydrophilic cross-linking monomer; and c) from 1.5% to less than 6% of transfer agent selected from alkyl halides and cycloaliphatic or aliphatic thiols having in particular from 2 to 24 carbon atoms, and optionally having another functional group selected from amino, hydroxy and carboxy groups. The invention further relates to a pharmaceutical composition comprising non-biodegradable embolisation microspheres according to the invention in conjunction with a pharmaceutically acceptable vehicle, advantageously for parenteral administration. The invention further relates to a kit comprising a pharmaceutical composition comprising non-biodegradable embolisation microspheres according to the invention in conjunction with a pharmaceutically acceptable vehicle for parenteral administration, and at least one injection means.